Will SARMs Show on a Drug Test?

What Standard Drug Tests Actually Screen For

Most employer-mandated and pre-employment drug tests use either a 5-panel or 10-panel immunoassay that targets cannabinoids, cocaine metabolites, amphetamines, opioids, and phencyclidine. Some 10-panel versions add benzodiazepines, barbiturates, methadone, propoxyphene, and methaqualone. None of these panels include SARMs, anabolic steroids, or peptide hormones.

The reason is cost and purpose. Immunoassay strips are calibrated for substances that federal agencies designated as drugs of abuse under the Controlled Substances Act. SARMs are not scheduled, so there has been no regulatory pressure to add them to the Department of Transportation or SAMHSA-mandated panels. A federally mandated workplace test will not flag LGD-4033, RAD-140, Ostarine (MK-2866), Cardarine (GW501516), or any other SARM variant currently circulating in the supplement market.

The SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs confirm that the federal workplace panel covers only the five drug classes above. If an employer orders a custom "expanded steroid panel" from a private lab, that is a different product entirely and could theoretically include SARMs, though this is uncommon outside professional sports organizations.

How Anti-Doping Tests Detect SARMs

WADA prohibited SARMs under Section S1.2 (Other Anabolic Agents) starting in 2008. Detection relies on liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS), a technology capable of identifying intact SARMs and their phase-I and phase-II metabolites at nanogram-per-milliliter concentrations.

A 2020 study published in Drug Testing and Analysis (PMID 32510860) characterized urinary metabolites for at least nine SARMs including LGD-4033, RAD-140, and S-23, establishing reference windows for accredited anti-doping laboratories. LGD-4033 glucuronide metabolites were detectable for up to 21 days after a single 1 mg oral dose. RAD-140 metabolites persisted for approximately 28 days after a single low dose.

A separate analysis of 10 years of adverse analytical findings (AAFs) submitted to WADA between 2012 and 2021 showed that SARMs accounted for a growing share of AAFs among recreational and amateur athletes, with Ostarine and LGD-4033 being the two most frequently identified compounds. WADA's 2023 Anti-Doping Rule Violations report documented over 400 SARMs-related AAFs globally in a single calendar year.

The U.S. military's drug testing program, administered through the Defense Health Agency, similarly uses expanded LC-MS/MS panels. Servicemembers have faced administrative action after testing positive for Ostarine from contaminated supplements, a scenario confirmed in multiple JAG case reviews.

HealthRX SARM Detection Risk Framework (for clinical counseling use):

| Compound | Half-life (approx.) | Urine Detection Window | Flagged by WADA Panel | |---|---|---|---| | Ostarine (MK-2866) | 24 hours | 7-10 days | Yes | | LGD-4033 (Ligandrol) | 24-36 hours | 21-28 days | Yes | | RAD-140 (Testolone) | 60 hours | 28+ days | Yes | | Andarine (S-4) | 4-6 hours | 7-10 days | Yes | | Cardarine (GW501516) | 16-24 hours | 14-21 days | Yes |

Detection windows reflect single low-dose exposures in controlled studies. Repeated dosing at bodybuilding-range quantities extends these windows materially. Half-life data are from available Phase I pharmacokinetic studies; no compound has completed Phase III trials.

Are SARMs Legal?

The legal status of SARMs in the United States sits in a gray zone that confuses most people. No SARM has received FDA approval for any indication. That means they cannot be legally marketed as dietary supplements or sold for human consumption.

The FDA issued a consumer alert in 2018 specifically warning against SARMs in bodybuilding products, stating they carry "serious safety concerns, including the potential to increase the risk of heart attack or stroke and life-threatening reactions like liver damage." Between 2017 and 2023, the FDA and FTC issued over 25 warning letters to companies selling SARMs-containing supplements. Possession for personal use is not a federal criminal offense under the Controlled Substances Act since SARMs are not scheduled, but selling them as supplements is illegal under the Federal Food, Drug, and Cosmetic Act.

The Designer Anabolic Steroid Control Act of 2014 expanded the Schedule III steroid list, but SARMs were deliberately excluded because their chemical structure differs from classical steroids. Legislation to schedule SARMs (the SARMs Control Act, introduced in 2018 and again in 2022) has not passed as of the date of this article. Several individual states have enacted their own restrictions.

Internationally, SARMs are controlled substances in Canada, Australia, and the United Kingdom, where possession without a prescription carries legal penalties.

Do SARMs Actually Build Muscle?

Early Phase I and Phase II clinical data do show lean mass gains, though the effect sizes are modest compared to supraphysiologic testosterone doses and no Phase III trial has been completed for any SARM marketed in the bodybuilding space.

A Phase II trial of Enobosarm (Ostarine) published in the Journal of Cachexia, Sarcopenia and Muscle (PMID 23109561) enrolled 159 patients with cancer-related muscle loss. At 3 mg per day for 16 weeks, Ostarine produced a statistically significant 1.3 kg increase in lean body mass compared to placebo (P<0.001). A dose of 1 mg produced 0.5 kg of lean mass gain. These were patients with active cancer cachexia, not healthy athletes starting from a normal baseline.

LGD-4033 was studied in a double-blind, placebo-controlled Phase I dose-escalation trial published in The Journals of Gerontology (PMID 23396204). Seventy-six healthy men received doses of 0.1 mg to 1.0 mg per day for 21 days. The 1.0 mg group gained a mean of 1.21 kg of lean body mass. Stair-climb power also improved significantly. The authors noted dose-dependent suppression of total testosterone and sex hormone-binding globulin.

The doses used in bodybuilding communities (10-30 mg per day for LGD-4033, for example) are 10 to 30 times higher than those studied in the above trial. No controlled safety or efficacy data exist at those doses, and the risk-to-benefit calculation changes substantially.

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital, stated in a 2020 editorial in the Journal of Clinical Endocrinology and Metabolism: "SARMs represent a promising area of investigation, but enthusiasm must be tempered by the absence of long-term safety data and the wide gap between clinical trial doses and those used by recreational athletes."

Do SARMs Suppress Testosterone and Require PCT?

Yes. LH and FSH suppression is documented at clinical trial doses. At bodybuilding doses, suppression is more pronounced.

The LGD-4033 Phase I trial cited above found that even 1 mg per day for 21 days suppressed free testosterone by approximately 55% from baseline. LH and FSH declined in parallel. Values returned to baseline within 5 weeks after cessation, but this was at a dose and duration far below what most recreational users report.

A case series published in Drug and Alcohol Dependence (PMID 34839040) described four young men presenting to an endocrinology clinic with symptomatic hypogonadism after SARM cycles. Total testosterone ranged from 42 to 187 ng/dL at presentation (reference range 300-1000 ng/dL). Three of the four had used multiple SARMs stacked together; one had used LGD-4033 alone for 12 weeks at 10 mg per day.

Post-cycle therapy (PCT) with clomiphene citrate (typically 25-50 mg per day for 4-6 weeks) or tamoxifen (20 mg per day for 4-6 weeks) is used off-label to restart the hypothalamic-pituitary-testicular axis after SARM suppression. Neither drug carries an FDA indication for this specific purpose. The Endocrine Society's clinical practice guideline on androgen deficiency (PMID 28359099) recommends against using anabolic agents in healthy eugonadal men for body-composition purposes and does not endorse SARMs for any off-label athletic use.

Recovery timelines vary. A man who ran 8 weeks of Ostarine at 15 mg per day may recover LH/FSH in 4-6 weeks without PCT. A man who stacked LGD-4033 plus RAD-140 for 16 weeks at high doses may experience suppression lasting 3-6 months, and some case reports document persistent hypogonadism requiring formal TRT evaluation.

How Do SARMs Compare to Anavar?

Oxandrolone (brand name Anavar) is a Schedule III controlled anabolic-androgenic steroid with an FDA-approved indication for weight gain after surgery, chronic infection, or severe trauma, and for bone pain associated with osteoporosis. SARMs have no FDA approval.

Anavar is often described as "mild" relative to other oral steroids, and in comparative terms it does carry lower hepatotoxicity risk than agents like methyltestosterone or oxymetholone. However, "mild" is relative. A systematic review published in Drug and Alcohol Dependence (PMID 30901538) confirmed that all oral 17-alpha-alkylated steroids, including oxandrolone, produce clinically meaningful elevations in liver enzymes (AST/ALT) and adversely alter lipid profiles, with HDL suppression averaging 20-30% in short cycles.

SARMs are not 17-alpha-alkylated, so they were initially expected to avoid hepatotoxicity. Clinical experience has challenged that assumption. The FDA's adverse event reporting system (FAERS) contains multiple cases of cholestatic jaundice attributed to RAD-140 and LGD-4033, and a case series in Annals of Internal Medicine (PMID 31060021) described three men hospitalized with drug-induced liver injury after using SARMs purchased online.

From a testing standpoint, the difference is significant. Oxandrolone and its metabolites are detectable on steroid panels for up to 4-6 weeks and are explicitly listed in WADA's S1.1 category. Anavar is a Schedule III controlled substance, meaning possession without a prescription is a federal criminal offense. SARMs are not scheduled and possession is not a criminal offense under federal law, though sale for human use remains illegal.

What Happens if You Test Positive for SARMs in Sport?

A positive SARM finding triggers an anti-doping rule violation under the World Anti-Doping Code regardless of the source (intentional use, contaminated supplement, or otherwise). The standard sanction is a four-year ban for first offenses involving non-specified substances. LGD-4033, RAD-140, and Cardarine are classified as non-specified; Ostarine occupies a more nuanced regulatory position in some jurisdictions.

The contaminated supplement defense does carry some weight. The Court of Arbitration for Sport has reduced sanctions in cases where an athlete demonstrated through batch testing that a commercial supplement contained an undisclosed SARM. The NSF Certified for Sport and Informed Sport programs test for SARMs, and athletes in tested sports should use only certified products.

A 2023 analysis of over-the-counter supplements tested by the FDA between 2017 and 2023 found that approximately 70% of products marketed for muscle building or fat loss and labeled as containing SARMs actually contained different compounds than listed, including unlabeled steroids and unapproved drugs.

Cardiovascular and Endocrine Risks Clinicians Should Know

SARMs are not benign. Three categories of risk appear consistently in the medical literature.

Cardiovascular risk is documented at the case level and in pharmacokinetic studies. Cardarine (GW501516), marketed alongside SARMs despite technically being a PPAR-delta agonist, was abandoned by GlaxoSmithKline after animal studies showed dose-dependent carcinogenesis across multiple tissue types. The NCI drug information database lists Cardarine as a carcinogen in animal models. RAD-140 has been associated with myocarditis in case reports submitted to FAERS.

Androgen receptor agonism in cardiac tissue has raised concern about hypertrophy and arrhythmia risk, mirroring concerns about classical AAS. Lipid abnormalities, specifically HDL suppression and LDL elevation, are documented for multiple SARMs in Phase I and II data.

Liver injury, as noted above, appears in both FAERS data and published case series. Total bilirubin, AST, ALT, and alkaline phosphatase should be checked at baseline and at 4-week intervals in any patient who discloses SARM use.

Endocrine disruption extends beyond testosterone suppression. A 2021 case report in the Journal of the Endocrine Society (PMID 34337299) described secondary adrenal insufficiency in a 24-year-old man after a prolonged SARM stack, a rare but documented complication requiring hydrocortisone replacement and several months of recovery.

Clinical Counseling Approach for Patients Using SARMs

Patients rarely disclose SARM use spontaneously. Direct, nonjudgmental questioning during intake about supplement use, "research chemicals," or bodybuilding compounds is the most effective strategy.

Baseline labs before any cycle disclosure should include: total and free testosterone, LH, FSH, SHBG, CBC, comprehensive metabolic panel (including AST, ALT, bilirubin, alkaline phosphatase), fasting lipid panel, and hematocrit. An EKG is reasonable for anyone over 35 or with cardiac risk factors.

Monitoring during use: lipid panel and liver function every 4 weeks. Post-cycle: repeat endocrine panel at 4, 8, and 12 weeks after last dose. If testosterone has not recovered to the patient's baseline by week 12, formal TRT evaluation is warranted.

Referral to endocrinology is appropriate for persistent hypogonadism, for lipid abnormalities requiring statin consideration, or for any elevation in bilirubin suggesting cholestasis.